BRAF and melanoma: The decrease on surface NKG2D-L, after BRAF-mutant melanoma cells in vitro treatment with vemurafenib and trametinib, was paralleled with a decrease in soluble and EV-associated proteins and suggested the evaluation of these biochemical forms in patient sera to follow up the evolution of immune modulating ligands and the reversal described by others at drug resistance.